Cargando…

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Metabolic reprogramming is widely known as a hallmark of cancer cells to allow adaptation of cells to sustain survival signals. In this report, we describe a novel oncogenic signaling pathway exclusively acting in mutated epidermal growth factor receptor (EGFR) non‐small cell lung cancer (NSCLC) wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Azhar, Levantini, Elena, Teo, Jun Ting, Goggi, Julian, Clohessy, John G, Wu, Chan Shuo, Chen, Leilei, Yang, Henry, Krishnan, Indira, Kocher, Olivier, Zhang, Junyan, Soo, Ross A, Bhakoo, Kishore, Chin, Tan Min, Tenen, Daniel G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840543/ https://www.ncbi.nlm.nih.gov/pubmed/29449326 http://dx.doi.org/10.15252/emmm.201708313

Ejemplares similares

CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer
por: Ali, Azhar, et al.
Publicado: (2019)

Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
por: Bollu, Lakshmi Reddy, et al.
Publicado: (2015)

Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis
por: Kadry, Yasmin A., et al.
Publicado: (2021)

CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR internalization and metabolism through recycling pathway: CD82 palmitoylation mutation can regulate the localization of EGFR
por: Bu, Jingya, et al.
Publicado: (2022)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

Protein Lipidation by Palmitoylation and Myristoylation in Cancer
por: Fhu, Chee Wai, et al.
Publicado: (2021)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer
por: Wang, Junxiong, et al.
Publicado: (2016)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Neural Palmitoyl-Proteomics Reveals Dynamic Synaptic Palmitoylation
por: Kang, Rujun, et al.
Publicado: (2008)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
por: Chin, Tan-Min, et al.
Publicado: (2020)

Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
por: Sugiyama, Michael G., et al.
Publicado: (2023)

Identification of biomarkers, pathways, and therapeutic targets for EGFR–TKI resistance in NSCLC
por: Zhu, Leilei, et al.
Publicado: (2023)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
por: Jones, Sylwia, et al.
Publicado: (2020)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Identification of Golgi-localized acyl transferases that palmitoylate and regulate endothelial nitric oxide synthase
por: Fernández-Hernando, Carlos, et al.
Publicado: (2006)

LncRNA DNAJC3-AS1 Regulates Fatty Acid Synthase via the EGFR Pathway to Promote the Progression of Colorectal Cancer
por: Tang, Yanyan, et al.
Publicado: (2021)

Characterization of Covalent-Reversible EGFR Inhibitors
por: Smith, Steven, et al.
Publicado: (2017)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

Quantification and Kinetic Analysis of Grb2-EGFR Interaction on Micro-Patterned Surfaces for the Characterization of EGFR-Modulating Substances
por: Lanzerstorfer, Peter, et al.
Publicado: (2014)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models
por: Polonio-Alcalá, Emma, et al.
Publicado: (2020)

Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan
por: Huang, Chun-Yao, et al.
Publicado: (2018)

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2022)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

Tenascin turns on the EGFR
por: Jegalian, Karin
Publicado: (2001)

Sweeter tumors with EGFR
por: Robinson, Richard
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_llbamc1tl0mfkfllht8t8gc80j